Advocacy intelligence hub — real-time data for patient organizations
Voranigo: FDA approved
treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) or isocitrate dehydrogenase-2 (IDH2) mutation following surgery including biopsy, sub-total resection, or gross total resection
St. Jude Children's Research Hospital — PHASE1, PHASE2
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Voranigo
(vorasidenib)Orphan drugServier Pharmaceuticals LLC
Isocitrate Dehydrogenase 1 Inhibitor [EPC]
12.1 Mechanism of Action Vorasidenib is a small molecule inhibitor that targets isocitrate dehydrogenase-1 and 2 (IDH1 and IDH2) enzymes. In vitro, vo...
Giles W. Robinson, MD, M.D
St. Jude Children's Research Hospital
📍 MEMPHIS, TN
Anna Vinitsky, MD, MS, MD
St. Jude Children's Research Hospital
📍 MEMPHIS, TN
Arnault Tauziède-Espariat
Sainte-Anne Hospital
Akira Baba
University of Michigan
Pinarbasi Emile
University of Michigan Medical School
Ryo Kurokawa
University of Michigan